Literature DB >> 20190193

Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.

Thomas A Paul1, Juraj Bies, Donald Small, Linda Wolff.   

Abstract

DNA hypermethylation of the p15INK4b tumor suppressor gene is commonly observed in acute myeloid leukemia (AML). Repressive histone modifications and their associated binding proteins have been implicated in the regulation of DNA methylation and the transcriptional repression of genes with DNA methylation. We have used high-density chromatin immunoprecipitation-on-chip to determine the histone modifications that normally regulate p15INK4b expression in AML cells and how these marks are altered in cells that have p15INK4b DNA methylation. In AML patient blasts without p15INK4b DNA methylation, a bivalent pattern of active (H3K4me3) and repressive (H3K27me3) modifications exist at the p15INK4b promoter. AML patient blasts with p15INK4b DNA methylation lose H3K4me3 at p15INK4b and become exclusively marked by H3K27me3. H3K27me3, as well as EZH2, extends throughout p14ARF and p16INK4a, indicating that polycomb repression of p15INK4b is a common feature in all AML blasts irrespective of the DNA methylation status of the gene. Reactivation of p15INK4b expression in AML cell lines and patient blasts using 5-aza-2'-deoxycytidine (decitabine) and trichostatin A increased H3K4me3 and maintained H3K27me3 enrichment at p15INK4b. These data indicate that AML cells with p15INK4b DNA methylation have an altered histone methylation pattern compared with unmethylated samples and that these changes are reversible by epigenetic drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190193      PMCID: PMC2858468          DOI: 10.1182/blood-2009-07-233858

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development.

Authors:  K Sakashita; K Koike; T Kinoshita; M Shiohara; T Kamijo; S Taniguchi; T Kubota
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

Authors:  J G Herman; C I Civin; J P Issa; M I Collector; S J Sharkis; S B Baylin
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia.

Authors:  T Uchida; T Kinoshita; T Ohno; H Ohashi; H Nagai; H Saito
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

4.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Authors:  M Levis; K F Tse; B D Smith; E Garrett; D Small
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

5.  Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation.

Authors:  M Schmidt; R Koller; P Haviernik; J Bies; K Maciag; L Wolff
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

6.  KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients.

Authors:  J E Dodge; C Munson; A F List
Journal:  Leuk Res       Date:  2001-10       Impact factor: 3.156

7.  The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells.

Authors:  Martina Schmidt; Juraj Bies; Tomohiko Tamura; Keiko Ozato; Linda Wolff
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma.

Authors:  Kazuya Sakuma; Ja-Mun Chong; Makoto Sudo; Tetsuo Ushiku; Yoko Inoue; Junji Shibahara; Hiroshi Uozaki; Hideo Nagai; Masashi Fukayama
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

9.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.

Authors:  G J Hannon; D Beach
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

Review 10.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.

Authors:  H G Drexler
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

View more
  37 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

2.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

3.  The tumor suppressor p15Ink4b regulates the differentiation and maturation of conventional dendritic cells.

Authors:  Joanna Fares; Richard Koller; Rita Humeniuk; Linda Wolff; Juraj Bies
Journal:  Blood       Date:  2012-03-28       Impact factor: 22.113

4.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.

Authors:  Meilan He; Wei Zhang; Thomas Bakken; Melissa Schutten; Zsolt Toth; Jae U Jung; Parkash Gill; Mark Cannon; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

5.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

6.  VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.

Authors:  Erick Riquelme; Milind Suraokar; Carmen Behrens; Heather Y Lin; Luc Girard; Monique B Nilsson; George Simon; Jing Wang; Kevin R Coombes; J Jack Lee; Waun Ki Hong; John Heymach; John D Minna; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

7.  Long noncoding RNA AFAP1-AS1 facilitates tumor growth through enhancer of zeste homolog 2 in colorectal cancer.

Authors:  Jianming Tang; Guansheng Zhong; Jianhui Wu; Haiyan Chen; Yongshi Jia
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

Review 8.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

9.  Three murine leukemia virus integration regions within 100 kilobases upstream of c-myb are proximal to the 5' regulatory region of the gene through DNA looping.

Authors:  Junfang Zhang; Jan Markus; Juraj Bies; Thomas Paul; Linda Wolff
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

Review 10.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.